Beruflich Dokumente
Kultur Dokumente
Name of Sponsor/Company: Individual Study Table Referring (For National Authority Use
to the Dossier Only)
Bristol-Myers Squibb
Name of Finished Product:
Sprycel
Name of Active Ingredient:
Dasatinib
SYNOPSIS
Final Clinical Study Report for Study CA180274
ABBREVIATED REPORT
TITLE OF STUDY: Randomized Phase II of CCNU Versus CCNU + dasatinib in Patients With
Recurrent Glioblastoma
INVESTIGATORS/STUDY CENTERS: 28 subjects were enrolled at 5 sites in Europe: 1 in France
(4 subjects), 1 in Italy (9 subjects), 2 in Netherlands (9 subjects), and 1 in Switzerland (6 subjects).
PUBLICATIONS: None
STUDY PERIOD: Study Initiation Date: 20-Oct-2009 CLINICAL PHASE: II
Study Completion Date: 31-Mar-2011
INTRODUCTION: This study was an exploratory trial, performed in close collaboration with the Brain
Tumor Group of the European Organization for Research and Treatment of Cancer (EORTC), to
investigate the combination of dasatinib with CCNU (lomustine) in patients with recurrent glioblastoma
(GBM). The study was designed to integrate a non-randomized safety cohort of at least 10 patients
(“run-in” phase ) aimed at documenting the safety profile and recommended dose of dasatinib when added
to standard CCNU, followed by a randomized Phase 2 which was to address the overall therapeutic strategy
on combining dasatinib and CCNU or CCNU alone. However, recruitment to the safety “lead-in” phase
was halted when the review of safety and laboratory data from this safety “lead-in” phase indicated that
administration of dasatinib in combination with CCNU was limited, also requiring reduction of the CCNU
dose. Thrombocytopenia was the major dose-limiting toxicity (DLT) encountered. Accordingly, the
randomized Phase 2 phase of the study was not performed. This abbreviated clinical study report provides a
summary of demography, disposition and safety data on all subjects treated in the safety “lead-in” phase
conducted at five sites. In addition, limited assessments of efficacy endpoints are also included.
OBJECTIVES: The general objectives of this study were to assess the safety of add-on dasatinib to
standard of care (CCNU) as well as to assess the activity of this add-on therapy in GBM patients who have
relapsed after standard therapy with temozolomide and radiotherapy. The primary end-point of the safety
“lead-in” phase was the safety and tolerance of dasatinib+CCNU combination in order to establish a
recommended dose for the Phase 2 part. A complete list of objectives are provided in the protocol.
METHODOLOGY: For the first 3 patients, cycle 1 was given with dasatinib at the dose of 100 mg QD
and escalated to 100 mg BID in cycle 2.
DL 1A DL 1B DL 2 DL 3A DL 3B Overall
(N=6) (N=3) (N=7) (N=9) (N=1) (N=26)
N (%) N (%) N (%) N (%) N (%) N (%)
Sex
male 5 (83.3) 3 (100.0) 5 (71.4) 6 (66.7) 1 (100.0) 20 (76.9)
female 1 (16.7) 0 (0.0) 2 (28.6) 3 (33.3) 0 (0.0) 6 (23.1)
Age
Median 58.8 57.7 53.6 49.7 51.1 54.8
Range 41.3 - 70.7 48.9 - 57.7 42.4 - 64.0 38.8 - 66.8 51.1 - 51.1 38.8 - 70.7
Histological diagnosis of
primary disease (by local
pathologist)
glioblastoma multiforme 6 (100.0) 2 (66.7) 5 (71.4) 8 (88.9) 1 (100.0) 22 (84.6)
glioblastoma with 0 (0.0) 1 (33.3) 2 (28.6) 1 (11.1) 0 (0.0) 4 (15.4)
oligodendroglial component
Performance status
0 6 (100.0) 2 (66.7) 1 (14.3) 4 (44.4) 1 (100.0) 14 (53.8)
1 0 (0.0) 1 (33.3) 5 (71.4) 4 (44.4) 0 (0.0) 10 (38.5)
2 0 (0.0) 0 (0.0) 1 (14.3) 1 (11.1) 0 (0.0) 2 (7.7)
Safety Results: An overview of safety data for all treated subjects is provided in Table 3.
Other Results - Pharmacokinetics of Dasatinib: There was no difference in the Cmax, Tmax, AUCinf and
half-life of dasatinib on Day 1 and Day 8 of Cycle 1.
CONCLUSIONS: The combination of dasatinib + CCNU was not well-tolerated, requiring both reduction
of CCNU dose and limitation of dasatinib exposure to levels below those planned. In addition, there was no
evidence of a treatment effect in this population. The lead-in phase was completed; however the tolerable
doses were below those expected to provide sufficient efficacy and thus the study did not proceed to the
randomized phase.